Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anika Therapeutics reports strong Q4 earnings, eyes growth opportunities

Anika Therapeutics delivered strong financial performance in Q4 2022, with revenue growth and strategic investments driving growth targets for 2023. The company is focused on product launches, expanding its portfolio, and preparing for the launch of the RevoMotion Reverse Shoulder System.
While facing challenges such as higher stock-based compensation and lower EBITDA expected in 2023, Anika remains optimistic about the value inflection point in 2023. The company's emphasis on growth initiatives and commercial optimization positions it for future opportunities.

Anika Therapeutics reports growth in core segments and strategic investments

Anika Therapeutics showed positive revenue growth in Q1, driven by core business segments.
Despite a net loss, Anika is strategically positioning itself as a global leader in joint preservation.
Investments in new products and regulatory progress with Cingal indicate a focus on innovation and expansion.
Maintaining strong gross margins amidst increased operating expenses highlights operational efficiency.

Anika Therapeutics posts robust Q2 results, eyes growth opportunities

Anika Therapeutics reported strong Q2 results, raising its revenue outlook for 2023.
Despite international challenges, the company sees opportunities for growth in key segments.
Progress in FDA approvals, partnerships, and new product launches position Anika for future success.
Maintaining a focus on innovation and market expansion will be crucial for sustained growth.

Anika Therapeutics raises guidance on strong Q3 performance and outlook

Anika Therapeutics showcased robust growth in key segments, leading to an optimistic outlook for the year. Despite challenges in restructuring sales operations, the company is well-positioned for continued success with a focus on profitability and new product launches.

Anika Therapeutics exceeds Q4 expectations, eyes Hyalofast's U.S. potential

Anika Therapeutics delivered robust financial performance, focusing on driving new products for growth and operational efficiency. The company aims to accelerate profitability targets and is on track with product launches, making strategic adjustments based on feedback.

Anika Therapeutics reports Q1 revenue growth and strategic product advancements

Anika Therapeutics demonstrated solid financial performance in Q1 2024, driven by revenue growth, cost reduction initiatives, and positive market feedback on key products.
While facing challenges such as FDA approval requirements and leadership transition, the company's strengths in product portfolio and distribution agreements position it well for future growth.
Opportunities in FDA designations, revenue growth expectations, and operational improvements present avenues for Anika to enhance market presence and financial performance in the coming quarters.

Anika Therapeutics reports Q3 revenue, focuses on core products

Anika Therapeutics faces challenges with workforce reduction and financial losses
However, strategic focus on core HA products and revenue reclassification show promise
Opportunities lie in revenue growth in the commercial channel and long-term investments
Overall, Anika Therapeutics aims for sustainable growth and value creation

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company's main focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and its products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

Avalo Therapeutics

CarGurus

Murphy USA

Western Gas Partners

MUSA, AVTX, ANIK, CARG and WES have been added to the Zacks Rank #1 (Strong Buy) List on December 14, 2023.

New Strong Buy Stocks for December 14th

Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion of its proprietary hyaluronic acid (HA) regenerative portfolio

Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will be participating at the following investor conferences:

Anika to Participate in Upcoming Investor Conferences

Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2023 Earnings Conference Call November 2, 2023 5:30 PM ET Company Participants Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications Cheryl Blanchard - President & Chief Executive Officer Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Mike Petusky - Barrington Research George Sellers - Stephens Inc Jim Sidoti - Sidoti & Company Operator Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript

Revenue Growth Exceeded Expectations in the Third Quarter and Year-To-Date, with Joint Preservation and Restoration up 14% and 10% and OA Pain Management up 2% and 11%, Respectively

Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business

BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Alcon Inc. - Registered Shares

Dr. Reddy's Labs

At this stage, it is prudent to invest in low-beta stocks with a favorable Zacks Rank like ALC, RDY and ANIK, as these will be less volatile than the broader market.

Protect Your Portfolio From Volatility With 3 Low-Beta Picks

RevoMotion Reverse Shoulder Arthroplasty System significantly expands Anika's shoulder arthroplasty portfolio and provides a bone conserving and innovative solution in the $1 billion1 U.S. reverse shoulder market

Anika Announces the Full Market Release of the RevoMotion™ Reverse Shoulder Arthroplasty System during the 2023 Orthopaedic Summit: Evolving Technologies (OSET) Annual Meeting

BEDFORD, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Thursday, September 21, 2023. Anika will host a virtual presentation with Q&A starting at 10:45am ET.

Anika to Participate in the Sidoti Small Cap Virtual Investor Conference

The heavy selling pressure might have exhausted for Anika (ANIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -20.42% in 4 Weeks, Here's Why You Should You Buy the Dip in Anika (ANIK)

Anika (ANIK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Anika (ANIK) Rating Upgrade to Buy

Anika (ANIK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Anika (ANIK) Loses -19.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Advanced Emissions Solutions

Nikola

While it is true that penny stocks can present good opportunities for exponential gains, this is not the case with these three. Maybe at some point they gave good results, but as economists know, there is the law of diminishing marginal returns, there comes a point in the trajectory of a penny stock where it is considerable to sell the position if you have been in it, and if that is not the case, it is better to omit these investment options.

3 Sorry Penny Stocks to Sell in August Before It's Too Late

Complete Integrity Implant System is now fully cleared; targeting launch in Q1-2024 Integrity is highly differentiated by its knitted structure, resulting in higher strength and greater regenerative capacity compared to first generation bovine collagen patches1 Integrity marks Anika's expansion of its proprietary regenerative portfolio and entrance into the over $150 million2 U.S. rotator cuff augmentation market BEDFORD, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the final 510(k) clearance from the FDA for the Integrity™ Implant System.

Anika Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.20 per share a year ago.

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

Double Digit Q2 Revenue Growth Driven by Strong OA Pain Management Growth of 22%; Raising Low-End of Full-Year Guidance Range on Positive Year-to-Date Performance

Anika Reports Second Quarter 2023 Financial Results

BEDFORD, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2023 financial results after the close of the market on Tuesday, August 8, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Anika's new X-Twist™ Fixation System, combined with its ACE Award-Winning Tactoset® for hardware augmentation and autologous bone morrow aspirate, provide time-saving regenerative solutions for Sports Medicine surgeons

Anika Showcases Highly Differentiated Joint Preservation and Restoration Portfolio at the 2023 AOSSM Annual Meeting

Hyalofast – a single-stage, off-the-shelf, resorbable, hyaluronic acid scaffold for cartilage repair –  is marketed in over 35 countries outside the U.S. where it has been clinically  demonstrated to be safe and effective

Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

Anika Therapeutics Inc. (NASDAQ:ANIK ) Q1 2023 Results Conference Call May 9, 2023 5:00 PM ET Company Participants Mark Namaroff - Executive Director of IR & Corporate Communications Cheryl Blanchard - President, CEO & Director Michael Levitz - Executive VP, CFO & Treasurer Conference Call Participants Harrison Parsons - Stephens Mike Petusky - Barrington Research Jim Sidoti - Sidoti Operator Good afternoon, ladies and gentlemen, and welcome to Anika's First Quarter 2023 Earnings Conference Call. [Operator Instructions] This call is being recorded on Tuesday, May 9, 2023.

Anika Therapeutics Inc. (ANIK) Q1 2023 Earnings Call Transcript

Anika Therapeutics (ANIK) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.20 per share a year ago.

Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11% Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%

Anika Reports First Quarter 2023 Financial Results

BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2023 financial results after the close of the market on Tuesday, May 9, 2023 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Anika to Issue First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Gary Fischetti Joins Anika Board Announces Share Repurchase Program Forms Capital Allocation Committee BEDFORD, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP (“Caligan”).

Anika Enters Into Cooperation Agreement with Caligan Partners

BEDFORD, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023. Anika will host a virtual presentation with Q&A starting at 12:45pm ET.

News for Anika Therapeutics Stock (ANIK)